MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF
Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B - streptococci, Viridans Streptococci, Enterococcus , or combinations thereof.
1 . A method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B - streptococci, Viridans Streptococci, Enterococcus , and combinations thereof.
2 . The method of claim 1 , wherein said salt is a hydrochloride salt.
3 . The method of claim 1 , wherein said salt is a tosylate salt.
4 . The method of claim 1 , wherein said subject is a human.
5 . The method of claim 1 , wherein said subject is suffering from injury, abscess, ulcer, or cellulitis.
6 . The method of claim 5 , wherein said injury is a trauma, surgery, bite, or burn.
7 . The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally.
8 . The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously.
9 . The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at dose of about 100 mg to about 300 mg per day.
10 . The method of claim 9 , wherein said 9-[(2,2-dimethyl-propyl amino minocycline is administered orally at a dose of about 200 mg per day.
11 . The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously at a dose of about 50 mg to about 150 mg per day.
12 . The method of claim 11 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered intravenously at a dose of about 100 mg per day.
13 . The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline has a clinical success rate of treating an infection of greater than about 93.2%.
14 . The method of claim 1 , wherein said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline has a microbiologically evaluable clinical success rate of treating an infection of greater than about 93.7%.
15 . A method of treating a subject for an infection, comprising administering to said subject an oral dose of about 100 mg to about 300 mg per day of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B - streptococci, Viridans Streptococci, Enterococcus , and combinations thereof, and further wherein said subject is in need of treatment thereof.
16 . A method of treating a subject for an infection, comprising administering to said subject an intravenous dose of about 50 mg to about 150 mg per day of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B - streptococci, Viridans Streptococci, Enterococcus , and combinations thereof, and further wherein said subject is in need of treatment thereof.
17 . A pharmaceutical composition comprising from about 100 to about 300 mg of 94(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier for oral administration.
18 . The pharmaceutical composition of claim 17 , wherein said composition comprises about 200 mg of said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.
19 . A pharmaceutical composition comprising from about 50 to about 150 mg of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof and a pharmaceutically acceptable carrier for intravenous administration.
20 . The pharmaceutical composition of claim 19 , wherein said composition comprises about 100 mg of said 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline.